India's trade deal with EFTA unlocks $100 billion investment opportunity
India has finalized a trade pact with the European Free Trade Association (EFTA), comprising Iceland, Liechtenstein, Norway and Switzerland, marking a significant milestone in international commerce.
EFTA members have proposed a substantial $100 billion investment in India over the next 15 years. The agreement aims to stimulate investment and collaboration while assisting India in diversifying its imports, reducing reliance on China. Sectors such as pharmaceuticals, biotechnology and chemicals, among others, are poised to benefit from extensive collaboration opportunities.
Prime Minister Narendra Modi and Iceland's Foreign Minister, Bjarni Benediktsson, both lauded the agreement, with Mr Modi terming it a "watershed moment" that fosters open, fair, and equitable trade practices, offering substantial benefits to all involved.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze